Anticancer Molecular Mechanisms of Resveratrol

Frontiers in Nutrition

Volumn 3, Issue , 2016, Pages

  Varoni, Elena M ^a   Lo Faro, Alfredo Fabrizio ^a   Sharifi Rad, Javad ^b   Iriti, Marcello ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

bioavailability; cancer chemoprevention; multi target agents; nutritional therapy; polyphenols; stilbenes

Indexed keywords

EID: 85079118879     PISSN: None     EISSN: 2296861X     Source Type: Journal    
DOI: 10.3389/fnut.2016.00008     Document Type: Review

References (74)

1. Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed (2015) 5:84–97.25949949
2. Rimando AM, Suh N. Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med (2008) 74:1635–43.10.1055/s-0028-108830118843589
3. Levi F, Pasche C, Lucchini F, Ghidoni R, Ferraroni M, La Vecchia C. Resveratrol and breast cancer risk. Eur J Cancer Prev (2005) 14:139–42.10.1097/00008469-200504000-0000915785317
4. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) (2009) 2:409–18.10.1158/1940-6207.CAPR-08-016019401532
5. Varoni EM, Lodi G, Iriti M. Efficacy behind activity – phytotherapeutics are not different from pharmaceuticals. Pharm Biol (2015) 53:404–6.10.3109/13880209.2014.923000
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646–74.10.1016/j.cell.2011.02.013
7. Lachenmeier DW, Godelmann R, Witt B, Riedel K, Rehm J. Can resveratrol in wine protect against the carcinogenicity of ethanol? A probabilistic ­dose-response assessment. Int J Cancer (2014) 134:144–53.10.1002/ijc.2833623784940
8. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res (2005) 49:472–81.10.1002/mnfr.20050001015779070
9. Zunino SJ, Storms DH. Physiological levels of resveratrol metabolites are ineffective as anti-leukemia agents against Jurkat leukemia cells. Nutr Cancer (2015) 67:266–74.10.1080/01635581.2015.98937325622018
10. Iriti I, Varoni E. Nutritional therapy: multitarget agents to prevent multifactorial diseases. Oncodrugs (2013) 1:1e–2e.
11. Iriti M, Varoni E. Biological and adjuvant therapies, new trends in oral cancer treatment. Oncodrugs (2014) 2:1e–2e.
12. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun (1999) 262:20–4.10.1006/bbrc.1999.115210448061
13. Diaz-Gerevini GT, Repossi G, Dain A, Tarres MC, Das UN, Eynard AR. Beneficial action of resveratrol: how and why? Nutrition (2016) 32:174–8.10.1016/j.nut.2015.08.01726706021
14. Iriti M, Faoro F. Health-promoting effects of grape bioactive phytochemicals. In: Watson RR, editor. Complementary and Alternative Therapies and the Aging Population. London: Academic Press (2009). p. 445.
15. Britton RG, Kovoor C, Brown K. Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann N Y Acad Sci (2015) 1348:124–33.10.1111/nyas.1279626099829
16. Kubota T, Uemura Y, Kobayashi M, Taguchi H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res (2003) 23:4039–46.14666716
17. Hogg SJ, Chitcholtan K, Hassan W, Sykes PH, Garrill A. Resveratrol, ­acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstet Gynecol Int (2015) 2015:279591.10.1155/2015/27959126617640
18. Strickland LR, Pal HC, Elmets CA, Afaq F. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 359:20–35.10.1016/j.canlet.2015.01.01625597784
19. Wong JC, Fiscus RR. Resveratrol at anti-angiogenesis/anticancer concentrations suppresses protein kinase G signaling and decreases IAPs expression in HUVECs. Anticancer Res (2015) 35:273–81.25550561
20. Bommareddy A, Eggleston W, Prelewicz S, Antal A, Witczak Z, McCune DF, et al. Chemoprevention of prostate cancer by major dietary phytochemicals. Anticancer Res (2013) 33:4163–74.24122979
21. Bhattacharya S, Darjatmoko SR, Polans AS. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res (2011) 21:180–7.10.1097/CMR.0b013e3283456dfc21407133
22. Sengottuvelan M, Deeptha K, Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem Biol Interact (2009) 181:193–201.10.1016/j.cbi.2009.06.00419523937
23. Gu S, Chen C, Jiang X, Zhang Z. Resveratrol synergistically triggers apoptotic cell death with arsenic trioxide via oxidative stress in human lung adenocarcinoma A549 cells. Biol Trace Elem Res (2015) 163:112–23.10.1007/s12011-014-0186-225431299
24. Mikuła-Pietrasik J, Sosińska P, Murias M, Wierzchowski M, Brewińska-Olchowik M, Piwocka K, et al. High potency of a novel resveratrol derivative, 3,3’,4,4’-Tetrahydroxy-trans-stilbene, against ovarian cancer is associated with an oxidative stress-mediated imbalance between DNA damage accumulation and repair. Oxid Med Cell Longev (2015) 2015:135691.10.1155/2015/135691
25. Kucinska M, Piotrowska H, Luczak MW, Mikula-Pietrasik J, Ksiazek K, Wozniak M, et al. Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: prooxidative potential of hydroxylated resveratrol analogs. Chem Biol Interact (2014) 209:96–110.10.1016/j.cbi.2013.12.00924398169
26. Yu X-D, Yang J-L, Zhang W-L, Liu D-X. Resveratrol inhibits oral squamous cell carcinoma through induction of apoptosis and G2/M phase cell cycle arrest. Tumour Biol (2015):1–7.10.1007/s13277-015-3793-426409447
27. Chelsky ZL, Yue P, Kondratyuk TP, Paladino D, Pezzuto JM, Cushman M, et al. Resveratrol analogue promotes ERKMAPK-dependent Stat3 serine and tyrosine phosphorylation alterations and antitumor effects in vitro against human tumor cells. Mol Pharmacol (2015) 88:524–33.10.1124/mol.115.099093
28. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res (2001) 7:1466–73.11350919
29. Kuo P-L, Chiang L-C, Lin C-C. Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci (2002) 72:23–34.10.1016/S0024-3205(02)02177-X12409142
30. Liao P-C, Ng L-T, Lin L-T, Richardson CD, Wang G-H, Lin C-C. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food (2010) 13:1415–23.10.1089/jmf.2010.112620946021
31. Adhami VM, Afaq F, Ahmad N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun (2001) 288:579–85.10.1006/bbrc.2001.581911676482
32. Cosco D, Paolino D, Maiuolo J, Marzio LD, Carafa M, Ventura CA, et al. Ultradeformable liposomes as multidrug carrier of resveratrol and ­5-fluorouracil for their topical delivery. Int J Pharm (2015) 489:1–10.10.1016/j.ijpharm.2015.04.05625899287
33. Yu X-M, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M, Chen H. Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther (2013) 12:1276–87.10.1158/1535-7163.MCT-12-084123594881
34. Polycarpou E, Meira LB, Carrington S, Tyrrell E, Modjtahedi H, Carew MA. Resveratrol 3-O-D-glucuronide and resveratrol 4’-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Mol Nutr Food Res (2013) 57:1708–17.10.1002/mnfr.201200742
35. Yang T, Wang L, Zhu M, Zhang L, Yan L. Properties and molecular mechanisms of resveratrol: a review. Pharmazie (2015) 70:501–6.
36. Basso E, Fiore M, Leone S, Degrassi F, Cozzi R. Effects of resveratrol on topoisomerase II-α activity: induction of micronuclei and inhibition of chromosome segregation in CHO-K1 cells. Mutagenesis (2013) 28:243–8.10.1093/mutage/ges06723462849
37. Demoulin B, Hermant M, Castrogiovanni C, Staudt C, Dumont P. Resveratrol induces DNA damage in colon cancer cells by poisoning topoisomerase II and activates the ATM kinase to trigger p53-dependent apoptosis. Toxicol In Vitro (2015) 29:1156–65.10.1016/j.tiv.2015.04.01525952326
38. Schroeter A, Groh IAM, Favero GD, Pignitter M, Schueller K, Somoza V, et al. Inhibition of topoisomerase II by phase II metabolites of resveratrol in human colon cancer cells. Mol Nutr Food Res (2015) 12:2448–59.10.1002/mnfr.20150035226455438
39. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev (2009) 130:528–37.10.1016/j.mad.2009.06.00519559722
40. Leone S, Basso E, Polticelli F, Cozzi R. Resveratrol acts as a topoisomerase II poison in human glioma cells. Int J Cancer (2012) 131:E173–8.10.1002/ijc.2735822095529
41. Lanzilli G, Fuggetta MP, Tricarico M, Cottarelli A, Serafino A, Falchetti R, et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol (2006) 28:641–8.16465368
42. Ren Z, Wang L, Cui J, Huoc Z, Xue J, Cui H, et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie (2013) 68:689–94.24020126
43. Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol (2015) 98:51–68.10.1016/j.bcp.2015.08.10526310874
44. Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ, et al. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther (2008) 15:133–9.10.1038/sj.cgt.770110318157146
45. Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol (2011) 301:F427–35.10.1152/ajprenal.00258.201021593185
46. Schirmer H, Pereira TCB, Rico EP, Rosemberg DB, Bonan CD, Bogo MR, et al. Modulatory effect of resveratrol on SIRT1, SIRT3, SIRT4, PGC1α and NAMPT gene expression profiles in wild-type adult zebrafish liver. Mol Biol Rep (2012) 39:3281–9.10.1007/s11033-011-1096-421706162
47. Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, Selvakumar D, et al. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun (2012) 424:371–7.10.1016/j.bbrc.2012.06.07522728882
48. Sin TK, Tam BT, Yu AP, Yip SP, Yung BY, Chan LW, et al. Acute treatment of resveratrol alleviates doxorubicin-induced myotoxicity in aged skeletal muscle through SIRT1-dependent mechanisms. J Gerontol A Biol Sci Med Sci (2015).10.1093/gerona/glv17526450947
49. Lou Y, Wang Z, Xu Y, Zhou P, Cao J, Li Y, et al. Resveratrol prevents doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of endoplasmic reticulum stress and the activation of the Sirt1 pathway. Int J Mol Med (2015) 36:873–80.10.3892/ijmm.2015.229126202177
50. Shi Q, Geldenhuys W, Sutariya V, Bishayee A, Patel I, Bhatia D. CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells. Genes Cancer (2015) 6:220–30.26124921
51. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther (2008) 7:3751–60.10.1158/1535-7163.MCT-08-056219074850
52. Li W, Ma J, Ma Q, Li B, Han L, Liu J, et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr Med Chem (2013) 20:4185–94.10.2174/0929867311320999025123992306
53. Zhong L-X, Li H, Wu M-L, Liu X-Y, Zhong M-J, Chen X-Y, et al. Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells. J Ovarian Res (2015) 8:25.10.1186/s13048-015-0152-425896424
54. Mikuła-Pietrasik J, Sosińska P, Ksiażek K. Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid. Gynecol Oncol (2014) 134:624–30.10.1016/j.ygyno.2014.06.02224995580
55. Gao Q, Yuan Y, Gan H-Z, Peng Q. Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis. Oncol Lett (2015) 9:2381–7.10.3892/ol.2015.298826137075
56. Qin Y, Ma Z, Dang X, Li W, Ma Q. Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the hedgehog signaling pathway. Mol Med Rep (2014) 10:2563–7.10.3892/mmr.2014.2511
57. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res (2009) 1:25–37.21188121
58. Zhang P, Li H, Yang B, Yang F, Zhang L-L, Kong Q-Y, et al. Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. Genes Cancer (2014) 5:154–64.25061499
59. Lin H, Xiong W, Zhang X, Liu B, Zhang W, Zhang Y, et al. Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncol Rep (2011) 26:925–30.10.3892/or.2011.138021743969
60. Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L, et al. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression. BMC Cancer (2015) 15:97.10.1186/s12885-015-1119-y25884904
61. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4’, 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal (2007) 2:7.10.1186/1750-2187-2-7
62. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem (2007) 304:273–85.10.1007/s11010-007-9510-x17636462
63. Harati K, Slodnik P, Chromik AM, Goertz O, Hirsch T, Kapalschinski N, et al. Resveratrol induces apoptosis and alters gene expression in human fibrosarcoma cells. Anticancer Res (2015) 35:767–74.25667456
64. Ma L, Li W, Wang R, Nan Y, Wang Q, Liu W, et al. Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis. Int J Oncol (2015) 47:1460–8.10.3892/ijo.2015.312426314326
65. Cai Y, Zhao L, Qin Y, Zhang M, He Y. Resveratrol inhibits proliferation and induces apoptosis of nasopharyngeal carcinoma cell line C666-1 through AMPK activation. Pharmazie (2015) 70:399–403.26189302
66. Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, et al. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 35(Suppl):S151–84.10.1016/j.semcancer.2015.03.00625951989
67. Latruffe N, Lançon A, Frazzi R, Aires V, Delmas D, Michaille J-J, et al. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann N Y Acad Sci (2015) 1348:97–106.10.1111/nyas.1281926190093
68. Inoue H, Nakata R. Resveratrol targets in inflammation. Endocr Metab Immune Disord Drug Targets (2015) 15:186–95.10.2174/187153031566615031612031625772176
69. Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol (2015) 309:G59–70.10.1152/ajpgi.00101.201426021807
70. Chin Y-T, Yang S-H, Chang T-C, Changou CA, Lai H-Y, Fu E, et al. Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status. Oncotarget (2015) 6:35866–79.10.18632/oncotarget.548226456774
71. Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ, Lee CW, et al. Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages. Int Immunopharmacol (2014) 22:303–10.10.1016/j.intimp.2014.07.00425042796
72. Ruotolo R, Calani L, Fietta E, Brighenti F, Crozier A, Meda C, et al. Anti-estrogenic activity of a human resveratrol metabolite. Nutr Metab Cardiovasc Dis (2013) 23:1086–92.10.1016/j.numecd.2013.01.00223465317
73. Zhang S, Cao HJ, Davis FB, Tang H-Y, Davis PJ, Lin H-Y. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer (2004) 91:178–85.10.1038/sj.bjc.660190215188005
74. Kjaer TN, Ornstrup MJ, Poulsen MM, Jørgensen JOL, Hougaard DM, Cohen AS, et al. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. Prostate (2015) 75:1255–63.10.1002/pros.2300625939591